When antibodies fall silent: reassessing Fusobacterium and prognosis in colorectal cancer

The enrichment of Fusobacterium nucleatum within colorectal cancer (CRC) tissue is among the most reproducible observations in cancer microbiome research. Since its initial identification in human colorectal tumors over a decade ago, Fusobacterium has been implicated in tumor progression, immune evasion, metastatic dissemination, and resistance to therapy (1). These findings have naturally prompted interest in identifying accessible biomarkers that might capture Fusobacterium exposure and inform prognosis. Against this backdrop, the study by Michaud and colleagues, evaluating pre-diagnostic antibody responses to 11 Fusobacterium proteins in relation to CRC-specific and overall survival within the EPIC cohort, offers a timely and necessary recalibration of expectations (2). At first glance, the primary conclusion appears discouraging: systemic antibody responses to Fusobacterium are not associated with survival in the overall CRC population, mirroring the authors’ own previous observations that Fusobacterium antibodies are likewise unassociated with CRC incidence (3). However, this result should not be interpreted as a refutation of Fusobacterium’s biological relevance. Rather, it exposes a fundamental mismatch between the localized biology of an onco-microbe and the systemic nature of the biomarkers being interrogated. At the same time, the age-specific signal observed in early-onset CRC suggests that under defined biological conditions, host immune responses to virulent Fusobacterium proteins may indeed carry prognostic meaning.

The oncogenic effects of Fusobacterium are local. Experimental and translational studies demonstrate that Fusobacterium promotes CRC progression through adhesion to tumor-expressed glycans, activation of inflammatory and autophagy-related signaling pathways, and suppression of antitumor immunity via engagement of inhibitory receptors such as TIGIT and CEACAM1 (4,5). These mechanisms operate within the tumor microenvironment, shaping immune architecture and therapeutic response. They do not rely on systemic infection, nor do they necessarily elicit durable circulating antibody responses. Viewed through this biological lens, the null findings reported by Michaud et al. in the overall EPIC cohort are not unexpected. Pre-diagnostic immunoglobulin G (IgG) responses measured years before cancer diagnosis are unlikely to reflect tumor-resident bacterial activity. Instead, seropositivity likely captures cumulative lifetime exposure, frequently originating from the oral cavity where Fusobacterium is a common constituent of periodontal biofilms (6). In older individuals, such exposure is prevalent, rendering antibody responses epidemiologically common but biologically nonspecific. The EPIC analysis therefore provides a rigorous demonstration that systemic serology is an inadequate proxy for localized microbial oncogenic activity in unselected CRC populations.

The most provocative aspect of the study emerges from age-stratified analyses. Among individuals diagnosed with CRC before age 55 years, seropositivity to specific Fusobacterium antigens, most notably Fn1893 and Fap2, was associated with substantially increased CRC-specific mortality (2). Although limited by sample size and wide confidence intervals, the magnitude and biological coherence of these associations merit careful consideration rather than dismissal. Early-onset CRC is increasingly recognized as a biologically distinct disease entity, enriched for unique molecular subtypes, immune landscapes, and environmental influences (7). Notably, the antigens implicated in this subgroup analysis are not generic bacterial components. Fn1893 and Fap2 are autotransporter adhesins involved in host interaction and immune modulation. Fap2, in particular, mediates Fusobacterium binding to tumor-associated glycans and directly suppresses cytotoxic immune responses through TIGIT engagement, thereby promoting immune escape (4,5). That antibody responses to these proteins identify worse outcomes is therefore highly instructive. These antibodies do not appear to reflect protective immunity. Instead, they may function as biomarkers of aggressive, microbiome-driven tumor biology, signaling host immune recognition in the setting of profound local immune suppression. This observation forces a critical re-evaluation of what microbial seropositivity represents in cancer epidemiology. In older-onset CRC, Fusobacterium antibodies likely reflect historical exposure with minimal relevance to tumor behavior. In early-onset CRC, however, the same serologic signal may signify active host-microbe engagement, systemic dissemination of virulent strains, or heightened immune recognition of tumors shaped by microbial immune evasion. In this sense, antibody responses may function less as indicators of exposure and more as markers of biological failure, identifying tumors in which immune surveillance has been effectively subverted.

Clinical and public health implications

These findings inevitably prompt consideration of whether Fusobacterium represents a tractable therapeutic or preventive target in colorectal cancer, particularly in early-onset disease. At present, such discussion should remain measured. Although antibiotic treatment, bacteriophage approaches, and microbiome modulation have demonstrated activity in preclinical models (8,9), their clinical translation is limited by concerns regarding durability, specificity, off-target effects on commensal microbiota, and uncertainty regarding optimal patient selection. As a result, broad antimicrobial strategies are unlikely to represent a scalable or long-term solution and should be viewed as exploratory rather than established therapeutic avenues. A more biologically grounded implication of this study lies in the specificity of the antigenic signals identified, rather than in global microbial eradication. The association between early-onset CRC outcomes and immune responses to Fn1893 and Fap2, virulence-associated autotransporter proteins involved in host interaction and immune suppression, suggests that these antigens may define a subset of biologically aggressive, microbiome-driven tumors (10). Importantly, antibody positivity in this context does not appear to reflect protective immunity. Instead, it may mark sustained exposure to immune-evasive Fusobacterium strains that actively remodel the tumor microenvironment and undermine effective antitumor surveillance (11). This distinction has meaningful translational implications. Rather than pursuing therapeutic strategies aimed at eliminating Fusobacterium broadly after tumor establishment, a more rational approach may involve antigen-directed prevention or early interception. Conceptually, vaccines targeting select Fusobacterium virulence proteins—such as Fap2 or Fn1893—could be developed to limit colonization, disrupt host-microbe interactions, or attenuate immune-evasive signaling before malignant transformation or early in tumor evolution (11,12). Such an approach would parallel other pathogen-targeted cancer prevention paradigms, in which immune priming against high-risk microbial antigens reduces downstream oncogenic potential rather than attempting to reverse advanced disease.

While highly speculative at present, this strategy is biologically aligned with the age-specific signal observed here. Early-onset CRC may represent a window in which microbial exposures exert a more direct influence on tumor biology, host immunity, and disease trajectory. In that setting, antigen-specific immune targeting could plausibly shift the balance from immune tolerance or suppression toward effective containment. Importantly, this framework emphasizes precision prevention, identifying individuals most likely to benefit based on microbial and immunologic risk signatures, rather than applying indiscriminate interventions across heterogeneous CRC populations.

Taken together, the study by Michaud and colleagues suggests that the greatest translational value of Fusobacterium-associated immune responses may not lie in their immediate clinical prognostic utility, but in their ability to illuminate actionable biology. By identifying specific microbial antigens linked to adverse outcomes in early-onset CRC, this work provides a rationale for future efforts focused on antigen-targeted prevention, immune interception, and biologically informed risk stratification approaches that may ultimately prove more impactful than conventional therapeutic strategies directed at the established tumor–microbiome ecosystem.

Future research directions

The findings of this study open several important avenues for future investigation. First, validation in independent cohorts is essential. Priority should be given to confirming the early-onset CRC associations in other large, well-characterized populations. International consortia may be particularly valuable for increasing the number of younger CRC cases, which remain a minority overall, and for testing the reproducibility of the Fn1893 and Fap2 signals. Parallel analyses in older patients would also be informative, as replicating the null findings in this group would strengthen the conclusion that age modifies the relationship between Fusobacterium immune responses and prognosis. Second, joint analysis of tumor tissue and serology is critical, as the authors have previously reported in a subset of tumors from the EPIC cohort (13). Measuring intratumoral Fusobacterium burden alongside systemic antibody responses within the same individuals would clarify how well seropositivity reflects active tumor colonization. It is plausible that only a subset of Fusobacterium-infected tumors elicits systemic antibody responses, depending on bacterial load, invasiveness, or host genetic and immunologic factors. Integrating tumor molecular features, such as microsatellite instability, CpG island methylator phenotype, or oncogenic mutations (e.g., BRAF, KRAS), may further explain why Fusobacterium appears more prognostically relevant in certain biological contexts, particularly in early-onset disease. Third, mechanistic studies dissecting systemic versus local immune responses are needed. The observation that antibody-positive early-onset patients experienced worse outcomes suggests that humoral immunity to Fusobacterium is not protective. Instead, antibody responses may reflect failed immune containment or delayed recognition of a highly immune-evasive tumor-microbiome ecosystem. Future work should examine whether cellular immune responses—such as Fusobacterium-specific T-cell activity, differ from humoral responses in their association with outcome. Distinguishing antibody isotypes [e.g., IgG versus mucosal immunoglobulin A (IgA)] may also yield insight into whether systemic versus mucosal immune engagement carries distinct biological implications.

Finally, translation toward microbial biomarkers and therapeutic strategies represents a logical next step. Diagnostic approaches may benefit from combined microbial signatures, integrating serology, stool-based microbial profiling, or multiplex polymerase chain reaction (PCR) assays that capture broader microbiome patterns rather than single organisms. On the therapeutic front, continued investigation into targeting Fusobacterium, through antibiotics, bacteriophages, microbiome modulation, or immune-based strategies, is warranted. Carefully designed clinical trials, such as adding anti-Fusobacterium interventions to standard therapy in biologically selected patients, will be necessary to determine whether disrupting this oncomicrobial axis can meaningfully improve outcomes. In parallel, novel approaches such as vaccination or targeted blockade of immune-evasive mechanisms (e.g., Fap2-TIGIT interactions) merit exploration.

Conclusions

This work encourages a more targeted and biologically informed perspective. Rather than asking whether Fusobacterium antibodies are prognostic for all patients, the more relevant question becomes: in which patients, and under what biological conditions, do Fusobacterium-related immune responses matter for cancer outcome? Addressing this question will require integrated efforts spanning epidemiology, microbiology, immunology, and clinical investigation. The authors are to be congratulated on leveraging a large-scale prospective cohort to challenge prevailing assumptions and generate new, testable hypotheses. The absence of association in the aggregate should not be mistaken for absence of relevance. Instead, it underscores a central lesson of microbiome research: context matters. Whether biomarkers such as Fn1893 or Fap2 antibodies remain intriguing observations or evolve into clinically actionable tools will depend on how effectively future studies embrace this biological complexity.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Annals of Cancer Epidemiology. The article did not undergo external peer review.

Funding: None.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://ace.amegroups.com/article/view/10.21037/ace-2026-1-0004/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Phipps AI, Hill CM, Lin G, et al. Fusobacterium nucleatum Enrichment in Colorectal Tumor Tissue: Associations With Tumor Characteristics and Survival Outcomes. Gastro Hep Adv 2025;4:100644. [Crossref] [PubMed]
2. Michaud DS, Platz EA, Garrett WS, et al. Antibody Responses to 11 Fusobacterium Proteins and Colorectal Cancer-Specific and Overall Survival in the EPIC Cohort. Cancer Epidemiol Biomarkers Prev 2026;35:88-94. [Crossref] [PubMed]
3. Butt J, Jenab M, Pawlita M, et al. Antibody Responses to Fusobacterium nucleatum Proteins in Prediagnostic Blood Samples are not Associated with Risk of Developing Colorectal Cancer. Cancer Epidemiol Biomarkers Prev 2019;28:1552-5. [Crossref] [PubMed]
4. Incognito D, Ciappina G, Gelsomino C, et al. Fusobacterium Nucleatum in Colorectal Cancer: Relationship Among Immune Modulation, Potential Biomarkers and Therapeutic Implications. Int J Mol Sci 2025;26:9710. [Crossref] [PubMed]
5. Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 2013;14:195-206. [Crossref] [PubMed]
6. Bolstad AI, Jensen HB, Bakken V. Taxonomy, biology, and periodontal aspects of Fusobacterium nucleatum. Clin Microbiol Rev 1996;9:55-71. [Crossref] [PubMed]
7. Turk A, Mondaca S, Nervi B, et al. Early-Onset Colorectal Cancer: From Genetic Discovery to Clinical Innovation. Am Soc Clin Oncol Educ Book 2025;45:e473618. [Crossref] [PubMed]
8. Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 2017;358:1443-8. [Crossref] [PubMed]
9. Löfmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 2010;50:S16-23. [Crossref] [PubMed]
10. Padma S, Patra R, Sen Gupta PS, et al. Cell Surface Fibroblast Activation Protein-2 (Fap2) of Fusobacterium nucleatum as a Vaccine Candidate for Therapeutic Intervention of Human Colorectal Cancer: An Immunoinformatics Approach. Vaccines (Basel) 2023;11:525. [Crossref] [PubMed]
11. Schöpf F, Marongiu GL, Milaj K, et al. Structural basis of Fusobacterium nucleatum adhesin Fap2 interaction with receptors on cancer and immune cells. Nat Commun 2025;16:8104. [Crossref] [PubMed]
12. Nakatsu G, Ko D, Michaud M, et al. Virulence factor discovery identifies associations between the Fic gene family and Fap2+ fusobacteria in colorectal cancer microbiomes. mBio. 2025;16:e0373224. [Crossref] [PubMed]
13. Genua F, Butt J, Waterboer T, et al. Association of Antibody Responses to Fusobacterium nucleatum and Streptococcus gallolyticus Proteins with Colorectal Adenoma and Colorectal Cancer. Dig Dis Sci 2023;68:3300-11. [Crossref] [PubMed]